885 related articles for article (PubMed ID: 19898258)
21. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
22. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
Motoshima K; Nakamura Y; Sano K; Ikegami Y; Ikeda T; Mizoguchi K; Takemoto S; Fukuda M; Nagashima S; Iida T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1299-1304. PubMed ID: 24121455
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
Minami S; Kijima T; Hamaguchi M; Nakatani T; Koba T; Takahashi R; Takeuchi Y; Kida H; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I
Lung Cancer; 2013 Nov; 82(2):271-5. PubMed ID: 23993733
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
[TBL] [Abstract][Full Text] [Related]
26. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Neal JW; Heist RS; Fidias P; Temel JS; Huberman M; Marcoux JP; Muzikansky A; Lynch TJ; Sequist LV
J Thorac Oncol; 2010 Nov; 5(11):1855-8. PubMed ID: 20975380
[TBL] [Abstract][Full Text] [Related]
27. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Goto K; Nishio M; Yamamoto N; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Fukuyama T; Tamura T
Lung Cancer; 2013 Oct; 82(1):109-14. PubMed ID: 23910906
[TBL] [Abstract][Full Text] [Related]
28. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
He C; Liu M; Zhou C; Zhang J; Ouyang M; Zhong N; Xu J
Int J Cancer; 2009 Nov; 125(10):2393-9. PubMed ID: 19530244
[TBL] [Abstract][Full Text] [Related]
29. Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.
Ikeda T; Nakamura Y; Yamaguchi H; Tomonaga N; Doi S; Nakatomi K; Iida T; Motoshima K; Mizoguchi K; Nagayasu T; Tsukamoto K; Kohno S
Clin Lung Cancer; 2012 Sep; 13(5):369-74. PubMed ID: 22410386
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
Takahashi T; Yamamoto N; Nukiwa T; Mori K; Tsuboi M; Horai T; Masuda N; Eguchi K; Mitsudomi T; Yokota S; Segawa Y; Ichinose Y; Fukuoka M; Saijo N
Anticancer Res; 2010 Feb; 30(2):557-63. PubMed ID: 20332470
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
33. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
34. XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Pietanza MC; Lynch TJ; Lara PN; Cho J; Yanagihara RH; Vrindavanam N; Chowhan NM; Gadgeel SM; Pennell NA; Funke R; Mitchell B; Wakelee HA; Miller VA
J Thorac Oncol; 2012 Jan; 7(1):219-26. PubMed ID: 22011666
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Inoue Y; Inui N; Asada K; Karayama M; Matsuda H; Yokomura K; Koshimizu N; Imokawa S; Yamada T; Shirai T; Kasamatsu N; Suda T
Cancer Chemother Pharmacol; 2015 Jul; 76(1):155-61. PubMed ID: 26003540
[TBL] [Abstract][Full Text] [Related]
36. Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.
Koinis F; Voutsina A; Kalikaki A; Koutsopoulos A; Lagoudaki E; Tsakalaki E; Dermitzaki EK; Kontopodis E; Pallis AG; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2018 Feb; 20(2):140-149. PubMed ID: 28631135
[TBL] [Abstract][Full Text] [Related]
37. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
38. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.
Jackman DM; Yeap BY; Lindeman NI; Fidias P; Rabin MS; Temel J; Skarin AT; Meyerson M; Holmes AJ; Borras AM; Freidlin B; Ostler PA; Lucca J; Lynch TJ; Johnson BE; Jänne PA
J Clin Oncol; 2007 Mar; 25(7):760-6. PubMed ID: 17228019
[TBL] [Abstract][Full Text] [Related]
39. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
40. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]